TXG – 10x Genomics, Inc.
TXG — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
14
Margin Of Safety %
-29
Put/Call OI Ratio
0.08
EPS Next Q Diff
-0.12
EPS Last/This Y
0.22
EPS This/Next Y
0.3
Price
21.83
Target Price
20.07
Analyst Recom
2.39
Performance Q
19.1
Upside
-156.1%
Beta
2.17
Ticker: TXG
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | TXG | 20.92 | 0.14 | 1.79 | 10018 |
| 2026-03-10 | TXG | 20.48 | 0.14 | 33.67 | 9987 |
| 2026-03-11 | TXG | 20.45 | 0.14 | 0.18 | 9988 |
| 2026-03-12 | TXG | 18.94 | 0.14 | 0.09 | 9988 |
| 2026-03-13 | TXG | 18.94 | 0.14 | 0.15 | 9988 |
| 2026-03-17 | TXG | 18.08 | 0.15 | 0.10 | 10615 |
| 2026-03-18 | TXG | 17.35 | 0.14 | 0.00 | 10983 |
| 2026-03-19 | TXG | 18.39 | 0.12 | 0.50 | 12066 |
| 2026-03-20 | TXG | 18.41 | 0.12 | 1.40 | 12066 |
| 2026-03-23 | TXG | 19.15 | 0.10 | 0.00 | 8520 |
| 2026-03-24 | TXG | 19.81 | 0.10 | 0.01 | 9060 |
| 2026-03-25 | TXG | 20.95 | 0.09 | 0.00 | 9654 |
| 2026-03-26 | TXG | 20.45 | 0.07 | 0.06 | 12144 |
| 2026-03-27 | TXG | 19.49 | 0.07 | 0.02 | 12391 |
| 2026-03-30 | TXG | 19.81 | 0.07 | 0.03 | 12598 |
| 2026-03-31 | TXG | 21.24 | 0.07 | 0.05 | 12817 |
| 2026-04-01 | TXG | 22.06 | 0.07 | 0.02 | 13296 |
| 2026-04-02 | TXG | 22.34 | 0.07 | 5.29 | 12732 |
| 2026-04-06 | TXG | 21.9 | 0.08 | 0.11 | 12071 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | TXG | 20.91 | 37.8 | -106.8 | -0.14 |
| 2026-03-10 | TXG | 20.44 | 37.8 | -102.1 | -0.14 |
| 2026-03-11 | TXG | 20.44 | 37.8 | -105.9 | -0.14 |
| 2026-03-12 | TXG | 18.95 | 37.8 | -93.0 | -0.14 |
| 2026-03-13 | TXG | 18.79 | 37.8 | -104.5 | -0.14 |
| 2026-03-17 | TXG | 18.09 | 37.8 | -121.4 | -0.14 |
| 2026-03-18 | TXG | 17.35 | 37.8 | -98.6 | -0.14 |
| 2026-03-19 | TXG | 18.36 | 37.8 | -107.5 | -0.14 |
| 2026-03-20 | TXG | 18.39 | 37.8 | -97.3 | -0.14 |
| 2026-03-23 | TXG | 19.15 | 37.8 | -104.1 | -0.14 |
| 2026-03-24 | TXG | 19.80 | 37.8 | -103.1 | -0.14 |
| 2026-03-25 | TXG | 20.92 | 37.8 | -106.6 | -0.14 |
| 2026-03-26 | TXG | 20.45 | 37.8 | -93.8 | -0.14 |
| 2026-03-27 | TXG | 19.50 | 37.8 | -89.8 | -0.14 |
| 2026-03-30 | TXG | 19.81 | 37.8 | -100.1 | -0.14 |
| 2026-03-31 | TXG | 21.22 | 37.8 | -109.2 | -0.14 |
| 2026-04-01 | TXG | 22.04 | 37.8 | -103.7 | -0.14 |
| 2026-04-02 | TXG | 22.34 | 37.8 | -99.6 | -0.14 |
| 2026-04-06 | TXG | 21.90 | 41.1 | -94.1 | -0.13 |
| 2026-04-07 | TXG | 21.83 | 41.1 | -96.8 | -0.13 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | TXG | -0.56 | 0.10 | 16.40 |
| 2026-03-10 | TXG | -0.56 | 0.10 | 16.40 |
| 2026-03-11 | TXG | -0.56 | 0.10 | 14.52 |
| 2026-03-12 | TXG | -0.56 | 0.10 | 14.52 |
| 2026-03-13 | TXG | -0.56 | 0.10 | 14.52 |
| 2026-03-17 | TXG | -0.56 | 3.07 | 14.52 |
| 2026-03-18 | TXG | -0.56 | 3.07 | 14.52 |
| 2026-03-19 | TXG | -0.56 | 3.07 | 14.52 |
| 2026-03-20 | TXG | -0.56 | 3.07 | 14.52 |
| 2026-03-23 | TXG | -0.56 | 3.08 | 14.52 |
| 2026-03-24 | TXG | -0.56 | 3.08 | 14.52 |
| 2026-03-25 | TXG | -0.66 | 3.08 | 14.00 |
| 2026-03-26 | TXG | -0.66 | 3.08 | 14.00 |
| 2026-03-27 | TXG | -0.66 | 3.08 | 14.00 |
| 2026-03-30 | TXG | -0.66 | 3.11 | 14.00 |
| 2026-03-31 | TXG | -0.66 | 3.11 | 14.00 |
| 2026-04-01 | TXG | -0.66 | 3.11 | 14.00 |
| 2026-04-02 | TXG | -0.66 | 3.11 | 14.00 |
| 2026-04-06 | TXG | -0.66 | 3.08 | 14.00 |
| 2026-04-07 | TXG | -0.66 | 3.08 | 14.00 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.07
Avg. EPS Est. Current Quarter
-0.06
Avg. EPS Est. Next Quarter
-0.05
Insider Transactions
-0.66
Institutional Transactions
3.08
Beta
2.17
Average Sales Estimate Current Quarter
146
Average Sales Estimate Next Quarter
148
Fair Value
15.61
Quality Score
44
Growth Score
41
Sentiment Score
69
Actual DrawDown %
89.6
Max Drawdown 5-Year %
-96.5
Target Price
20.07
P/E
Forward P/E
PEG
P/S
4.34
P/B
3.5
P/Free Cash Flow
21.42
EPS
-0.35
Average EPS Est. Cur. Y
-0.13
EPS Next Y. (Est.)
0.17
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-6.77
Relative Volume
0.77
Return on Equity vs Sector %
-32.9
Return on Equity vs Industry %
-15
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
-96.8
◆
TXG
Healthcare
$21.82
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
58.6
Range 1M
82.8%
Sup Dist
1.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-138.3%
EPS NY
23.9%
52W%
89.6%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-46.5% upside
Upside
-46.5%
Quality
44
MoS
-29%
10x Genomics, Inc.Sector: Healthcare
Industry: Health Information Services
Employees: 1178
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
TXG
Latest News
—
Caricamento notizie per TXG…
stock quote shares TXG – 10x Genomics, Inc. Stock Price stock today
news today TXG – 10x Genomics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch TXG – 10x Genomics, Inc. yahoo finance google finance
stock history TXG – 10x Genomics, Inc. invest stock market
stock prices TXG premarket after hours
ticker TXG fair value insiders trading